Pancreatic adenocarcinoma is known for early aggressive local invasion, high metastatic potential, and a low 5-year survival rate. Matrix metalloproteinases (MMPs) play important roles in tumor growth and invasion. Earlier studies on pancreatic cancer have found increased expression of certain MMPs to correlate with poorer prognosis, short survival time or presence of metastases. We studied the expression of MMP-21, -26, and tissue inhibitor of matrix metalloproteinases ( Keywords: matrix metalloproteinase; adenocarcinoma; tissue inhibitor of metalloproteinase Pancreatic cancer is one of the most lethal types of cancer: the 5-year survival rate of pancreatic adenocarcinoma is under 5%.1,2 Other types of pancreatic tumors (15% of all tumors) include insulinoma, gastrinoma, and carcinoid tumor. Pancreatic cancer is notorious for its late clinical presentation, early and aggressive local invasion, and metastatic potential.3 The diagnosis is confirmed using ultrasound combined with biopsy as well as computed tomography, and tumor markers such as CA 19-9. If metastases are not found, the Whipple operation (pancreaticoduodenectomy) is performed to remove the tumor. If metastases are detected, palliative treatments are chosen, such as biliary bypass procedure or chemo/radiotherapy. A known risk factor for pancreatic cancer is smoking, which increases the risk two-to three-fold. 4 Also, patients with chronic pancreatitis have increased risk for developing pancreatic carcinoma. 5,6